scholarly article | Q13442814 |
P50 | author | Christopher P Cannon | Q90608635 |
P2093 | author name string | Cong Chen | |
John Viscusi | |||
Peter M Dibattiste | |||
Sean P Curtis | |||
Tuli Ahmed | |||
P2860 | cites work | Prediction of Coronary Heart Disease Using Risk Factor Categories | Q22241923 |
Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials | Q24546221 | ||
Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III) | Q27860959 | ||
Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group | Q28138338 | ||
High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease | Q28181305 | ||
C-reactive protein and other inflammatory risk markers in acute coronary syndromes | Q28195425 | ||
Risk of acute myocardial infarction with nonselective non-steroidal anti-inflammatory drugs: a meta-analysis | Q28200524 | ||
Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial | Q28217835 | ||
Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q28218927 | ||
??? | Q28199855 | ||
Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines | Q29619614 | ||
Intensive versus moderate lipid lowering with statins after acute coronary syndromes | Q29619716 | ||
Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention | Q29620087 | ||
C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? | Q33678964 | ||
Reporting of noninferiority and equivalence randomized trials: an extension of the CONSORT statement | Q33993977 | ||
Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities | Q34245387 | ||
Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies | Q34469221 | ||
Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial. | Q34575707 | ||
Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison | Q34582722 | ||
Clinical application of C-reactive protein for cardiovascular disease detection and prevention | Q35054464 | ||
Old and new cardiovascular risk factors: from unresolved issues to new opportunities | Q35603920 | ||
Established and emerging plasma biomarkers in the prediction of first atherothrombotic events | Q35822621 | ||
Plasma homocysteine concentration, statin therapy, and the risk of first acute coronary events | Q40646293 | ||
A prospective study of fibrinogen and risk of myocardial infarction in the Physicians' Health Study | Q40818460 | ||
Influence of fibrinogen on cardiovascular disease | Q41635547 | ||
Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events | Q44216708 | ||
The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis | Q45088909 | ||
Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. | Q51574876 | ||
Fibrinogen and risk of cardiovascular disease. The Framingham Study. | Q52588834 | ||
Plasma total homocysteine and cardiovascular and noncardiovascular mortality: the Hordaland Homocysteine Study | Q74196327 | ||
Etoricoxib | Q80471891 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | placebo | Q269829 |
biomarker | Q864574 | ||
P304 | page(s) | 4-13 | |
P577 | publication date | 2008-07-01 | |
P1433 | published in | Archives of Drug Information | Q15753799 |
P1476 | title | A Comparison of Cardiovascular Biomarkers in Patients Treated for Three Months with Etoricoxib, Celecoxib, Ibuprofen, and Placebo | |
P478 | volume | 1 |